Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease
Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, Urashima M
The American journal of clinical nutrition · 158 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2013-03-13 · Am J Clin Nutr · vol. 97 · número 5 · págs. 1004–1013
- Editorial
- Elsevier BV
- Citado
- 222 citas · más que el 99% de estudios similares · 12.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Parkinson's Disease Mechanisms and Treatments · Nuclear Receptors and Signaling
- Palabras clave
- Parkinson's disease, vitamin D3 supplementation, vitamin D receptor, FokI polymorphism, disease progression, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale, genetic interactions, 25-hydroxyvitamin D, motor symptoms, non-motor symptoms
- MeSH
- humans, parkinson disease, disease progression, calcium, dietary, cholecalciferol, parathyroid hormone, receptors, calcitriol, body mass index, endpoint determination, follow-up studies, double-blind method, blood pressure, genotype, dietary supplements, aged, middle aged, female, male, surveys and questionnaires
7 autores
- Masahiko Suzuki🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Masayuki Yoshioka🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Masaya Hashimoto🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Maiko Murakami🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Miki Noya🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Daisuke Takahashi🇯🇵Jikei University School of Medicine; Katsushika Medical Center
- Mitsuyoshi Urashima🇯🇵Jikei University School of Medicine; Katsushika Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
In our previous study, higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and the vitamin D receptor (VDR) FokI CC genotype were associated with milder Parkinson disease (PD).
Objective
We evaluated whether vitamin D3 supplementation inhibits the progression of PD on the basis of patient VDR subgroups.
Design
Patients with PD (n = 114) were randomly assigned to receive vitamin D3 supplements (n = 56; 1200 IU/d) or a placebo (n = 58) for 12 mo in a double-blind setting. Outcomes were clinical changes from baseline and the percentage of patients who showed no worsening of the modified Hoehn and Yahr (HY) stage and Unified Parkinson's Disease Rating Scale (UPDRS).
Results
Compared with the placebo, vitamin D3 significantly prevented the deterioration of the HY stage in patients [difference between groups: P = 0.005; mean ± SD change within vitamin D3 group: +0.02 ± 0.62 (P = 0.79); change within placebo group: +0.33 ± 0.70 (P = 0.0006)]. Interaction analyses showed that VDR FokI genotypes modified the effect of vitamin D3 on changes in the HY stage (P-interaction = 0.045), UPDRS total (P-interaction = 0.039), and UPDRS part II (P-interaction = 0.021). Compared with the placebo, vitamin D3 significantly prevented deterioration of the HY stage in patients with FokI TT [difference between groups: P = 0.009; change within vitamin D3 group: -0.38 ± 0.48 (P = 0.91); change within placebo group, +0.63 ± 0.77 (P = 0.009)] and FokI CT [difference between groups: P = 0.020; change within vitamin D3 group: ±0.00 ± 0.60 (P = 0.78); change within placebo group: +0.37 ± 0.74 (P = 0.014)] but not FokI CC. Similar trends were observed in UPDRS total and part II.
Conclusion
Vitamin D3 supplementation may stabilize PD for a short period in patients with FokI TT or CT genotypes without triggering hypercalcemia, although this effect may be nonspecific for PD. This trial was registered at UMIN Clinical Trials Registry as UMIN000001841.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.